SCHEMBL13628260

SCHEMBL13628260

O=C1/C(=N\O)c2ccc(-c3ccccc3C(F)(F)F)cc2N1Cc1cc(F)cc2c1OCOC2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.39
POLB P06746 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
TSHR P16473 2/20 0.33
GALR3 O60755 1/20 0.33
NR2F2 P24468 1/20 0.33
MAPK8 P45983 1/20 0.33
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
CXCR5 P32302 1/20 0.31
CHRM1 P11229 1/20 0.30
DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628264 0.88 POLB (0.36) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628065 0.88 NPC1 (0.37) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628263 0.88 HCRTR1 (0.34) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628259 0.86 MAPK8 (0.36) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628090 0.86 POLB (0.36) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13627961 0.86 MAPK8 (0.40) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628285 0.85 PRF1 (0.35) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628295 0.85 POLB (0.36) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628290 0.84 POLB (0.34) CHRM5POLBNPC1RAB9ANPSR1
SCHEMBL13628150 0.83 MAPK8 (0.38) CHRM5POLBNPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CHRM5 4815/4885POLB 2623/4885NPC1 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.